KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Non-cash Items (2018 - 2021)

Aquestive Therapeutics (AQST) has 4 years of Non-cash Items data on record, last reported at $6.7 million in Q1 2021.

  • For Q1 2021, Non-cash Items fell 22.88% year-over-year to $6.7 million; the TTM value through Mar 2021 reached $6.7 million, down 22.88%, while the annual FY2020 figure was $1.2 million, 205.69% up from the prior year.
  • Non-cash Items reached $6.7 million in Q1 2021 per AQST's latest filing, up from $1.2 million in the prior quarter.
  • Across five years, Non-cash Items topped out at $12.4 million in Q1 2019 and bottomed at $87000.0 in Q4 2018.
  • Average Non-cash Items over 4 years is $6.6 million, with a median of $7.4 million recorded in 2020.
  • Peak YoY movement for Non-cash Items: surged 364.37% in 2019, then crashed 38.63% in 2020.
  • A 4-year view of Non-cash Items shows it stood at $87000.0 in 2018, then soared by 364.37% to $404000.0 in 2019, then skyrocketed by 205.69% to $1.2 million in 2020, then skyrocketed by 442.83% to $6.7 million in 2021.
  • Per Business Quant database, its latest 3 readings for Non-cash Items were $6.7 million in Q1 2021, $1.2 million in Q4 2020, and $6.6 million in Q3 2020.